Back to first-pass browser

First-pass extracted concept

TLR4/opioid receptor pathway crosstalk

Candidate: concept label1 source documents6 linked claims
Jump to explainersJump to evidenceJump to sourcesJump to claims
Live refresh every 5sNext refresh in 5s

Extracted Explainers

What the tool is doing

This concept describes bidirectional or convergent signaling interactions between TLR4 and opioid receptor pathways. The review frames it as varying by cell type, stimulus, and downstream signaling context.

Source 1DOIPubMed

What problem it solves

It helps explain why opioids can be associated with both neuroinflammatory and immunosuppressive outcomes. It also provides a mechanistic frame for altered analgesia and other opioid effects.

Source 1DOIPubMed

What it does not solve

It is not itself a discrete engineered tool, assay, or construct. The abstract does not provide a standardized intervention or protocol built around this concept.

Source 1DOIPubMed

Alternatives

The review contrasts central TLR4-linked pro-inflammatory signaling with peripheral inhibition of LPS-induced TLR4 signaling rather than presenting a separate alternative framework.

Source 1DOIPubMed

Evidence Snippets

This review summarizes the following types of TLR4/opioid receptor pathway crosstalk...
Evidence 1Source 1DOIPubMedprovenance

Supporting Sources

Linked Claims

Claim 1context dependence summarysupports2020Source 1DOIPubMed

The review states that opioid receptor agonists inhibit LPS-induced TLR4 signaling in peripheral immune cells, indicating that TLR4/opioid receptor crosstalk depends on cell type and activating stimulus.

Claim 2mechanistic summarysupports2020Source 1DOIPubMed

The review states that intracellular TLR4/opioid receptor crosstalk induces formation of a β-arrestin-2/TRAF6 complex that contributes to morphine-induced inhibition of LPS-induced TNF-α secretion in mast cells.

Claim 3mechanistic summarysupports2020Source 1DOIPubMed

The review states that opioid receptor agonists can non-stereoselectively activate TLR4 signaling in the CNS in the absence of LPS, leading to NF-κB activation and pro-inflammatory cytokine production.

Claim 4mechanistic summarysupports2020Source 1DOIPubMed

The review states that opioid receptor agonists induce HMGB1 production, and HMGB1 acts as an endogenous TLR4 agonist that can support intercellular inflammatory interactions.

Claim 5pathway convergence summarysupports2020Source 1DOIPubMed

The review states that both TLR4 and opioid receptor pathways activate MAPK signaling and that this downstream convergence can contribute to pro-inflammatory effects in the CNS.

Claim 6proposed feedback modelsupports2020Source 1DOIPubMed

The review describes a proposed positive feedback loop in persistent sensitization involving morphine-induced IL-1β release followed by increased DAMP release, which further increases activation of TLR4 and P2X7R.